linjc16/ctgov huggingface dataset:
Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla.(Group B ) A Randomized Controlled Clinical Trial

Study Overview
=================
Brief Summary
-----------------
20 patients were selected requiring implant placement and divided randomly into two groups (10 in each group) for the study group, starter drill is used to locate the point of insertion as planned then pilot drill is also used to the full desired working length after that all other sequential drills are used at a low speed (50-70 rpm) without irrigation . In the study group: implant will be inserted in the low speed osteotomy site. In the control group: implants will be inserted in the conventional prepared osteotomy site. For both groups there is no surgical guide used. The flap will then be copiously irrigated with saline in preparation for closure. The flap will then be closed using interrupted 4/0 resorbable sutures.

Official Title
-----------------
Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial

Conditions
-----------------
Bone Resorption

Intervention / Treatment
-----------------
* Procedure: Drilling at low speed
* Procedure: Drilling at conventional or high speed


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients restoring missing maxillary teeth with implant placement. Both sexes. Age: 25-45 Mesio-distal dimensions: Not less than 6 mm Bone Height: Not less than 12 mm Bucco-lingual dimensions: Not less than 8mm All measures will be assessed using CBCT. Exclusion Criteria: Sites needing bone grafting or augmentation. Heavy smokers more than 20 cigarettes per day. Patients with systemic disease that may affect normal healing.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Biologic drilling<br>drilling at low speed | Procedure: Drilling at low speed<br> <br> |
| Active Comparator: conventional drilling<br>drilling at conventional or high speed | Procedure: Drilling at conventional or high speed<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| crestal bone loss | measurement from radiographic analysis using digital periapical x-ray | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient morbidity after procedure | pain value on pain scale | 1 day | 
| Implant stability value | resonance frequency analysis using osstell | 3 month |
A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face

Study Overview
=================
Brief Summary
-----------------
This study is to determine whether a medication on the market for other indications is effective and safe in treating seborrheic dermatitis of the face.

Detailed Description
-----------------
To test the efficacy and safety of azelaic acid 15% gel in the treatment of seborrheic dermatitis of the face

Official Title
-----------------
A Double-Blind, Randomized, Vehicle-Controlled, Six-Week Exploratory Multicenter Pilot Study of the Efficacy and Safety of Azelaic Acid (AzA) 15% Gel in the Topical Treatment of Mild to Moderate Seborrheic Dermatitis of the Face

Conditions
-----------------
Seborrheic Dermatitis on the Face

Intervention / Treatment
-----------------
* Drug: Azelaic Acid 15% Gel
* Drug: Inactive 15% gel base


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Stable or exacerbating seborrheic dermatitis in the facial area Exclusion Criteria: Psoriasis Atopic dermatitis Facial acne and rosacea Dermatophytic skin infections Parkinson's disease Known immunosuppression; HIV infection Any condition requiring continuous systemic or topical corticosteroid or antimycotic therapy Continuous asthma inhalation treatment requiring > 800 mg corticosteroids Any severe disease likely to interfere with the conduct or the planned termination of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>azelaic acid 15% | Drug: Azelaic Acid 15% Gel<br>* 15% gel, topically applied daily for six weeks<br>|
| Placebo Comparator: 2<br>Inactive 15% gel base | Drug: Inactive 15% gel base<br>* placebo, topically applied daily for six weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sum Score of the symptoms of seborrheic dermatitis and the investigator's global assessment. |  | Measurement of parameters during the course of treatment (six weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Investigators' and patients' subjective assessment of improvement; frequency and intensity of single symptoms |  | Measurement of parameters during the course of treatment (six weeks) |
Covid-19, Acute Myocardial Infarctions and Strokes in France

Study Overview
=================
Brief Summary
-----------------
The COVID-19 pandemic has had dramatic effects on health systems and on non-COVID health care. Using French inpatient claims data and retrospectively collected clinical data, the investigators will assess the changes in hospital admissions for acute cardiovascular and neurovascular conditions in France during and after the national lockdown.

Official Title
-----------------
Impact of COVID-19 on Unplanned Admissions for Acute Cardiovascular and Neurovascular Conditions in France

Conditions
-----------------
COVID-19, Acute Cardiovascular Condition, Acute Neurovascular Condition, Stroke, Acute Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - Adults admitted in 2018, 2019 or 2020 in a French hospital for acute coronary syndrom or stroke Exclusion criteria: - None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID-19 period<br>Admissions from January to December 2020 | |
| Control period<br>Admissions from January 2018 to December 2019 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daily number of admissions for acute cardio- and neurivascular conditions in France. | Daily number of admissions for acute cardio- and neurivascular conditions in France. | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Specific mortality rate. | Specific mortality rate. | 1 day |
Evaluation and Comparison of Two Biomarkers (VOP and SCC) for the Prognosis of the Occurrence of Clinical Cardiovascular Events

Study Overview
=================
Brief Summary
-----------------
The aim of our study is to assess the Cardiovascular risk and the quality of the arteries by comparing the Coronary Calcium Score SCC measured with a CT scann and the Pulse Wave Velocity PWV measured with pOpmeter for the prognosis at 6 months of clinical events. Is there a superiority of PWV compared to SCC:

Detailed Description
-----------------
Two method of cardiovascular risk screening are compared in patient going for Coronary Calcium Score measurement in a outpatient clinic. Ct Scann is expensive, learning time is for at least 2 years, and the reliability is operator dependent. The Pulse Wave Velocity is measured using a new device with half an hour learning curve, and you get a result within 2 minutes. A non-invasive medical device vs invasive A better benefit-risk ratio A lower diagnostic cost both for equipment and for qualification for use and learning time

Official Title
-----------------
Evaluation and Comparison of Two Biomarkers (VOP and SCC) for the Prognosis of the Occurrence of Clinical Cardiovascular Events

Conditions
-----------------
Cardiovascular Risk Factor

Intervention / Treatment
-----------------
* Device: CCS wit CT Scann measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject aged over 18 Any Patient referred to the Bizet Clinic for a CT scan of the coronary arteries Subject affiliated to a social security scheme or beneficiary of such a scheme Lack of participation in another clinical study Exclusion Criteria: Minor patient Patient with obliterating arterial disease of the lower limbs Patient with Sore fingers and hands Patient with arrhythmia that does not allow measurement of VOP Patient with limb amputation Major subject protected by law, under curatorship or tutorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients undergoing CT scann for CCS determination<br> | Device: CCS wit CT Scann measurement<br>* Measurement with 2 devices<br>* Other names: PWV measurement with pOpmètre;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Coronary Calcium Score | Coronary Calcium Score, | 12 months | 
| Pulse Wave Velocity |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulse Wave Velocity, Coronary Calcium Score,, Cardiovascular event,, Cardiovascular risk factor
The Effect of Pilates and Elastic Taping on Balance and Postural Control in Early Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to compare the effects of pilates training and elastic taping on balance and postural control in early Parkinson's patients.

Detailed Description
-----------------
The subjects were randomly divided into 3 groups as pilates, elastic taping and waiting list control group. Individuals were given 60-minute pilates training twice a week for 6 weeks. In addition to Pilates training, elastic taping was applied twice a week for postural correction of the back. Individuals were evaluated for balance and postural control before and after training. Evaluation of clinical balance with Berg Balance Scale and Trunk Impairment Scale; Stability Limits, Sits Up, Normal and Tandem Walking Tests were performed with NeuroCom Balance Master balance and performance system.

Official Title
-----------------
The Effect of Pilates and Elastic Taping on Balance and Postural Control in Early Parkinson's Disease

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Other: Pilates
* Other: Elastic taping


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Idiopathic Parkinson Disease Mini Mental Test Score≥24 Modified Hoehn and Yahr Score≤2 Ability to stand 1 minute independently Ability to walk 10 meters Exclusion Criteria: Other orthopaedic, neurologic or visual disease which could affect ability of balance and walking Unstabl cardiovasvularly disease History of Surgery about Parkinson disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pilates<br> | Other: Pilates<br>* In pilates group: Pilates training twice a week for 6 weeks.<br>* Other names: Elastic Taping;|
| Experimental: Elastic Taping<br> | Other: Elastic taping<br>* Elastic taping group: Elastic taping application after the pilates training twice a week for 6 weeks Wait List<br>|
| No Intervention: Wait List Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Balance | Walk Across Test were performed with Neurocom Balance Master System. | 7.5 months | 
| Postural control | Stability Limits Test was performed with Neurocom Balance Master System. | 7.5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pilates, Balance, Postural control, Early Parkinson's Disease, Elastic Taping
Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po

Study Overview
=================
Brief Summary
-----------------
This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to require acid-suppressive therapy following a course of intravenous (iv) pantoprazole (PROTONIX ® I.V. for Injection).

Official Title
-----------------
A Randomized, Open-Label, Comparative, Two-Treatment, Crossover Study of the 24-Hour Intragastric pH Profile After 5 Days of Once Daily Oral Administration of Either Esomeprazole 40 mg or Pantoprazole 40 mg Following Once Daily Infusion of Intravenous Pantoprazole 40 mg for 5 Days in Healthy Volunteer Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Esomeprazole
* Drug: pantoprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provision of informed consent. Males and females aged 18 to 70 years, inclusive. Male or non-pregnant, nonlactating female healthy volunteer subjects. Females must be post-menopausal, surgically sterilized, or using a medically acceptable form of birth control, as determined by the investigator. Women of childbearing potential must agree to continue using an acceptable form of birth control throughout the conduct of the study. Exclusion Criteria: Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the investigational site) Previous enrollment or randomization of treatment in the present study. Received an experimental drug or used an experimental device within 28 days preceeding the screening visit.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Esomeprazole|nan|
|Drug: pantoprazole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percent time of intragastric pH>4.0 on oral dosing Day 5 during the 24-hour intragastric pH monitoring period. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percent time of intragastric pH>4.0 on oral dosing Day 1 and the mean hourly cumulative IGA during the 24-hour intragastric pH monitoring periods (on oral dosing Days 1 and 5. |  |  |
MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel

Study Overview
=================
Brief Summary
-----------------
Background. Allergic Contact Dermatitis (ACD) is an inflammatory skin disease mediated by direct contact with allergens as nickel, the most common allergen, that may be related with epigenetic changes. Objective. Evaluate the miR-126 expression and its target VCAM-1, in the skin of patients with ACD to nickel. Methods. Fifteen patients with positive patch test to nickel were included, and the expression of miR-126 and VCAM-1 was evaluated by RT-qPCR.

Detailed Description
-----------------
Patients that went to the dermatology and outpatient department of the Central Hospital Dr. Ignacio Morones Prieto , with a suspected diagnosis of nickel allergic contact dermatitis, were invited to participate in this study. Later, the objective and methodology of the study were explained to them, as well as the advantages of participating and the possible undesirable effects. All patients signed the informed consent previous perfom the medical history. After, the epicutaneous patch test was performed, and patients were divided according to the result them. Finally, under local anesthesia, two 3-mm punch biopsies, from lesional (positive parch test site) and adjacent non lesional skin, 10 cm apart, were performed. Tissues for reverse transcriptase real-time polymerase chain reaction (RT-qPCR) analyses were stored frozen in sterile tubes at 80ºC until processing

Official Title
-----------------
Alteration of the microRNA-126 Expression: a Possible Mechanism in Allergic Contact Dermatitis to Nickel

Conditions
-----------------
Allergic Contact Dermatitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age and older Epicutaneous Patch Test positive to Nickel without previous treatment within the previous 4 weeks Exclusion Criteria: Pregnancy nursing menopause consumption of any type of drugs (including anti-inflammatories and hormonal treatments) within the previous 2 months coexistence of other dermatoses conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| positive ACD to nickel<br>Patients with positive epicutaneous patch test to nickel | |
| negative ACD to nickel<br>Patients with negative epicutaneous patch test to nickel | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expression of miR-126 | Relative expression of the miR-126 on skin biopsies from ACD patients | 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
allergic contact dermatitis, nickel, microRNAs, VCAM-1
Transcranial Electrical Stimulation (TES) for the Treatment of Depression.

Study Overview
=================
Brief Summary
-----------------
This study is a RCT of transcranial electrical stimulation in depressed patients. Mood, cognitive test performance and biomarkers will be measured during the trial.

Conditions
-----------------
Major Depression

Intervention / Treatment
-----------------
* Device: Sham TES
* Device: Active TES


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DSM-IV Major Depressive Episode (as part of a Major Depressive Disorder or Bipolar Disorder), of minimum 4 weeks duration. MADRS score ≥ 20 at study entry. Exclusion Criteria: DSM-IV psychotic disorder; drug or alcohol abuse or dependence (preceding 12 months); inadequate response to ECT (current episode of depression); anticonvulsant or benzodiazepine medication; rapid clinical response required, e.g. high suicide risk; clinically defined neurological disorder or insult; metal in the cranium, skull defects, or skin lesions on scalp (cuts, abrasions, rash) at proposed electrode sites; pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Active TES<br>Active TES | Device: Active TES<br>* Neuroconn Eldith device<br>|
| Sham Comparator: Sham TES<br>Sham TES | Device: Sham TES<br>* Neuroconn Eldith device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Montgomery Asberg Depression Rating Scale for Depression (MADRS) |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Beck Depression Inventory II |  | 12 weeks |